Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07502703

Validation of Remote Photoplethysmography (rPPG)-Derived Cardiovascular Parameters Against Standard Clinical Measurements and Risk Scores in a Community

The goal of this observational study is to evaluate whether a contactless camera-based technology, called remote photoplethysmography (rPPG), can accurately measure cardiovascular parameters and estimate cardiovascular risk in adults aged 30 years and older living in a community setting in Semanan, Jakarta. This study aims to determine if rPPG can be used as a simple and accessible tool for early cardiovascular screening.

The main questions it aims to answer are:

1. Do cardiovascular parameters measured using rPPG (such as blood pressure, heart rate, and cardiac workload) agree with standard clinical measurements? 2. Do cardiovascular risk estimates generated by rPPG (such as ASCVD risk and Framingham heart age) correspond to risk calculations obtained using conventional clinical and laboratory methods?

Researchers will compare results obtained from rPPG-based facial video scans with results from standard medical assessments, including blood pressure measurements, heart rate evaluation, and laboratory tests for cholesterol levels, to determine the level of agreement and accuracy.

Participants will:

1. Undergo a short facial video scan (approximately 30-60 seconds) using an rPPG-based system 2. Receive standard clinical assessments, including blood pressure and heart rate measurements 3. Provide basic health information (such as age, sex, smoking status, and treatment history) Undergo simple laboratory testing for cholesterol levels

This study is expected to help determine whether rPPG can be used as a reliable, non-invasive, and scalable screening tool for cardiovascular risk in community and primary healthcare settings.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

30 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Kelurahan Semanan

Jakarta, Jakarta Special Capital Region, Indonesia

Location contact

Alexander Halim Santoso

PRINCIPAL_INVESTIGATOR

Alya Dwiana

SUB_INVESTIGATOR

Amita Pradhani

SUB_INVESTIGATOR

Bryan Anna Wijaya

SUB_INVESTIGATOR

Clement Drew

SUB_INVESTIGATOR

David Wongso

SUB_INVESTIGATOR

Diana Dinali

SUB_INVESTIGATOR

Enny Irawaty

SUB_INVESTIGATOR

Ernawati Ernawati

PRINCIPAL_INVESTIGATOR

Hanna Wijaya

CONTACT

[email protected]

+6281223787878

Muhammad Fikri Dzakwan

SUB_INVESTIGATOR

Silviana Tirtasari

SUB_INVESTIGATOR

Steve Geraldo Bustam

SUB_INVESTIGATOR

Triyana Sari

SUB_INVESTIGATOR

Wenny Sanwani

CONTACT

[email protected]

+6281585013412

Wikrama Lokapradhana

SUB_INVESTIGATOR

William Kuswandi

SUB_INVESTIGATOR

Zita Atzmardina

SUB_INVESTIGATOR

About this study

Introduction Remote photoplethysmography (rPPG) is an emerging contactless technology that enables extraction of physiological signals from facial video, allowing estimation of cardiovascular parameters such as heart rate and blood pressure. With the growing burden of atherosclerotic cardiovascular disease (ASCVD), early and accessible risk screening tools are essential, particularly in community settings with limited access to laboratory-based assessments. Although established risk models such as the ASCVD and Framingham scores are widely used, their application often requires clinical and laboratory data that may not be readily available. The integration of rPPG-based measurements with cardiovascular risk estimation offers a promising approach; however, its clinical validity and agreement with standard methods remain insufficiently explored .

Objective This study aims to evaluate the agreement and concordance between rPPG-derived cardiovascular parameters and standard clinical measurements, as well as to assess the alignment of rPPG-estimated ASCVD risk and Framingham heart age with conventional risk calculations.

Methods This study will use an analytical observational cross-sectional design conducted in Kelurahan Semanan, Jakarta. Adult participants (≥30 years) will be recruited through community-based sampling. Each participant will undergo clinical anamnesis, physical examination (blood pressure and heart rate), and laboratory testing (total cholesterol and HDL). In parallel, rPPG-based facial video scans will be performed under standardized conditions to obtain systolic and diastolic blood pressure, mean arterial pressure, pulse pressure, heart rate, cardiac workload, ASCVD risk, and Framingham heart age. Framingham risk will be calculated using sex-specific equations based on clinical and laboratory variables. Agreement between rPPG and standard measurements will be assessed using Bland-Altman analysis, while correlations will be evaluated using Pearson or Spearman tests. Concordance for categorical risk classification will be analyzed using Cohen's Kappa.

Expected Results It is expected that rPPG-derived heart rate will demonstrate good agreement with standard measurements, while blood pressure parameters will show moderate agreement. Additionally, rPPG-based ASCVD risk and Framingham heart age are anticipated to exhibit acceptable concordance with conventional risk calculations. These findings may support the potential role of rPPG as a preliminary screening and risk stratification tool in community-based and telemedicine settings.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged ≥30 years
  • Willing to participate and provide informed consent
  • Able to undergo face scan, clinical examination, and laboratory testing

Exclusion criteria

  • Facial abnormalities interfering with rPPG signal acquisition
  • Inability to remain still during measurement
  • Severe clinical instability
  • Incomplete key variables

Treatment and study plan

Primary outcomes

  1. Agreement of rPPG-Derived Blood Pressure with Standard Measurements

    Time frame: Day 1

    Assessment of agreement between systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), and pulse pressure obtained from rPPG-based facial video analysis and standard measurements using aneroid or digital sphygmomanometers. Agreement will be evaluated using Bland-Altman analysis (mean difference and limits of agreement).

  2. Agreement of rPPG-Derived Heart Rate and Cardiac Workload

    Time frame: Day 1

    Evaluation of agreement between heart rate and cardiac workload obtained from rPPG and those measured using standard methods (palpation and pulse oximetry). Agreement will be analyzed using Bland-Altman and correlation analysis (Pearson/Spearman).

  3. Concordance of rPPG-Based ASCVD Risk with Standard Risk Calculation

    Time frame: Day 1

    Assessment of agreement and concordance between ASCVD risk (%) and risk categories (low, intermediate, high) estimated using rPPG and those calculated using conventional clinical and laboratory data. Concordance will be evaluated using Cohen's Kappa and correlation analysis.

  4. Concordance of rPPG-Derived Framingham Heart Age

    Time frame: Day 1

    Evaluation of agreement between Framingham heart age estimated using rPPG-derived parameters and heart age calculated using standard Framingham risk equations based on clinical and laboratory variables. Agreement will be assessed using correlation and Bland-Altman analysis.

Study contacts

Contact information is provided by the study sponsor or research team.

Alexander Halim Santoso, MD

CONTACT

[email protected]

+6281381606869

Ernawati Ernawati, Dr

CONTACT

[email protected]

+6281389048199

Sponsors and collaborators

Lead sponsor

Tarumanagara University

Other

Registry information

Official study title

Validation of Remote Photoplethysmography (rPPG)-Derived Cardiovascular Parameters Against Standard Clinical Measurements and Risk Scores in a Community-Based Population in Semanan, Jakarta

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Mar 31, 2026
Registry last updated
Apr 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.